Likewise, the NPM1 mutation is considered to be an AML-defining genetic abnormality, also forming the entity of AML with mutated NPM1 in the European Leukemia Net (ELN) 2022 Guidelines [31]. This evidence concerns the gene NPM1 and acute myeloid leukemia.